BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Samuel K. Sia

eRA COMMONS USER NAME (credential, e.g., agency login): samsia

POSITION TITLE: Professor, Biomedical Engineering

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
University of Alberta (Edmonton, AB, Canada) Harvard University (Cambridge, MA, USA) Harvard University (Cambridge, MA, USA)	B.Sc. Ph.D. Postdoc	05/1997 05/2002 05/2005	Biochemistry Biophysics Chemistry & Chem. Biol.

A. Personal Statement

My research group has developed novel technologies for soft microdevices and for point-of-care diagnostics, both in an academic and industry setting (as a founder and chair of scientific advisory board of Claros Diagnostics, a startup company that has recently garnered European regulatory approval for a diagnostics product). Our work in miniaturized medical devices has garnered coverage from over 400 press outlets, including Nature, Science, JAMA, Washington Post, BBC, NPR, Voice of America, Science News, Popular Science, Chemical and Engineering News, and MIT Technology Review. Towards practical translational research, I am also founder of a biotech incubator facility with New York City that has hosted over 40 biotech companies.

B. Positions and Honors

<u>Positions</u>		
2016 -	Professor, Department of Biomedical Engineering, Columbia University	
2014 -	Faculty Co-Director of Entrepreneurship, School of Engineering and Applied Sciences,	
	Columbia University	
2011-2016	Associate Professor, Department of Biomedical Engineering, Columbia University	
2005-2011 -	Assistant Professor, Department of Biomedical Engineering, Columbia University	
Significant Professional Activities (2010-current)		

<u>Olgrinioant i r</u>	orodolonal 7 tolivilio (2010 darroni)
2018	Chair, NIH Study Section (ZAI1 RB-A)
2016-2018	Reviewer (DP2, U19, and special-emphasis mechanisms), NIH
2015	Chair, NIH Study Section (ZAI1 EC-M (S1))
2015	Keynote speaker, Select Bio Conference (Berlin), 3/18/15
2014	Invited speaker, EuroLabFocus (Liverpool, England), 10/9/14
2014	Invited speaker, ESOF EuroScience (Copenhagen, Denmark), 6/25/14
2014	Invited speaker, AACC Conference (San Jose, CA), 4/24/14
2013	Plenary session keynote speaker, 3rd Annual International Conference on Tropical Medicine,
	Florida International University
2012	Plenary speaker, NIH/AID International Research in Infectious Diseases Annual Meeting

2012	Plenary speaker, ISLH 2012, Nice, France
2012	Invited participant, NIH/NHLBI Working Group on Point of Care Technologies for Cardiovascular
	Clinical Research
2012	Invited speaker, NIH/NINR Annual Roundtable
2011	External Advisory Board Member, UC Berkeley Center for Neglected Diseases
2011	Invited speaker, NIH/NCI, Cancer Diagnostics for Global Health
2011	Member, NSF Review Panel (ECCS)
2011	Invited speaker, Symposium on innovative approach to infectious-disease diagnostics, Harvard
	Medical School
2011	External Committee Reviewer, NIH/NIAID Western Regional Center of Excellence for
	Biodefense and Emerging Infectious Diseases Research (Galveston TX)
2010	Keynote speaker, Henry Wheeler Center for Emerging and Neglected Diseases, UC Berkeley
2010	Featured speaker, MIT Emerging Technologies Conference
2010	CDRMP reviewer
2010	Member, NSF Review panel (EPDT)
2010	Member, organizing committee, National Academy of Engineering Frontiers of Engineering
	Indo-American Conference (2010)
2010	Chair, Northeast Bioengineering Conference (2010)
2005-	Referee for journals: Science, Nature Materials, Nature Chemistry, Nature Reviews Drug
	Discovery, Nature Communications, Proc. Natl. Acad. Sci., Lab on a Chip, Anal. Chem., and
	others

Entrepreneurial Activities

2013- Co-Founder, Harlem Biospace (biotech incubator started with NYC's Mayor's Office)

2009- Founder and President, Junco Labs

2004-2011 Co-Founder and Chair of Scientific Advisory Board, Claros Diagnostics (sold in 2011 to OPKO

Health, NYSE: OPK). In November 2017, OPKO has filed a Premarket Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for a CLIA-waived Total PSA test

with the Claros® 1 immunoassay analyzer. The filing contains clinical data from the Company's

864-patient Total PSA clinical study.

http://investor.opko.com/news-releases/news-release-details/opko-health-submits-premarket-

approval-application-fda-point

Significant Honors and Awards

<u>Orgininoanici</u>	Tionore and 7 than ac
2016	Inducted Fellow, American Institute for Medical and Biological Engineering (AIMBE)
2015	Thiele Lectureship Award, University of Notre Dame
2013	Kjeldgaard International Lectures in Molecular Biology, Aarhus Denmark
2011	Runner-up, Wall Street Journal Innovation Award in Medical Devices
2010	NASA Launch, one of ten innovators in human health and sustainability
2010	MIT Technology Review 35 Innovators Under 35
2009	Invited attendee, National Academies Keck Futures Initiative, UC Irvine
2008-2010	Wallace H. Coulter Early Career Award Phase II
2008-2013	NSF CAREER Award
2007	Invited participant, National Academy of Engineering Frontiers of Engineering, Seattle
2006-2008	Walter H. Coulter Early Career Award
2006-2010	American Heart Association Scientist Development Grant
2004-2005	Canadian Institutes of Health Research Fellowship (postdoc)
2002	Harvard University Certificate of Distinction in Teaching

world from all disciplines chosen to attend)
1997-2002 Howard Hughes Medical Institute Predoctoral Fellowship

C. Contributions to Science

2002

1. **Medical diagnostic devices.** My lab developed integrated point-of-care diagnostic devices that could detect protein biomarkers from a drop of blood. Our lab was among the first to directly demonstrate that

Delegate, International Achievement Summit, Dublin, Ireland (1 of 200 graduate students in the

integrated devices containing lab-on-a-chip technology can be used for this purpose as tested in field settings. Our approach has focused on low-cost manufacturable plastic substrates, and involves collaborators in public health, medicine, and industry. We are now working to develop these devices for infectious diseases, chronic diseases and wellness for global health and consumer health, in combination with consumer electronics devices.

- a. Nayak S, Sridhara A, Melo R, Richer L, Chee NH, Kim J, Linder V, Steinmiller D, Sia SK*, Gomes-Solecki M*, "Microfluidics-based point-of-care test for serodiagnosis of Lyme Disease", *Scientific Reports*, 2016 Oct 11;6:35069. doi: 10.1038/srep35069.
- b. T. Laksanopin, T.W. Guo, S. Nayak, A.A. Sridhara, S. Xie, O.O. Olowookere, P. Cadinu, F. Meng, N.H. Chee, J. Kim, C.D. Chin, E. Munyazesa, P. Mugwaneza, A.J. Rai, V. Mugisha, A.R. Castro, D. Steinmiller, V. Linder, J.E. Justman, S. Nsanzimana, S.K. Sia, (2015). A smartphone dongle for diagnosis of infectious diseases at the point of care. *Science Translational Medicine*, 7:273re1.
- c. T. Guo, R. Patnaik, K. Kuhlmann, A.J. Rai, S.K. Sia, "Smartphone dongle for simultaneous measurement of hemoglobin concentration and detection of HIV antibodies", *Lab Chip*, 15:3514-20 (2015).
- d. C.D. Chin, Y.K. Cheung, T. Laksanasopin, M.M. Modena, S.Y. Chin, A.A. Sridhara, D. Steinmiller, V. Linder, J. Mushingantahe, G. Umviligihozo, E. Karita, L. Mwambarangwe, S.L. Braunstein, J. van de Wijgert, R. Sahabo, J.E. Justman, W. El-Sadr, <u>S.K. Sia</u>, "Mobile device for disease diagnosis and data tracking in resource-limited settings", *Clin. Chem.*, 59, 629-640 (2013).
- 2. 3D biomaterial microfabrication. My lab has developed novel high-resolution methods to control the microenvironment around cells. These methods enable precise control over three-dimensional cellular environments. Our lab has used these methods for two sets of applications: engineering tissues with improved function, as well as understanding tissue development to high resolution. We are now working to apply these methods to problems of high clinical significance.
 - a. S.Y. Chin, Y.C. Poh, A. Kohler, J.T. Compton, L.L. Hsu, K.M. Lau, S. Kim, B.W. Lee, F.Y. Lee and <u>S.K. Sia</u>, "Additive manufacturing of hydrogel-based materials for next-generation implantable medical devices", *Science Robotics*, eaah6451 (2017).
 - b. N. Tejavibulya and *S.K. Sia, "Personalized Disease Models on a Chip", *Cell Systems*, 3(5):416-418 (2016).
 - c. O. Ordeig, S.Y. Chin, S. Kim, P.V. Chitnis, <u>S.K. Sia</u>, "An implantable compound-releasing capsule triggered on demand by ultrasound", *Scientific Reports*, 6:22803 (2016).
 - d. G. Eng, B.W. Lee, H. Parsa, C.D. Chin, J. Schneider, G. Linkov, <u>S.K. Sia</u>, G. Vunjak-Novakovic, "Assembly of complex cell microenvironments using geometrically docked hydrogel shapes", *Proc. Natl. Acad. Sci.*, 110, 4551-4556 (2013).
- 3. **Protein design and engineering.** My undergraduate and PhD work focused on using structural biology and protein engineering to develop improved peptide-based inhibitors of viral entry.
 - a. <u>S.K. Sia</u>, P.S. Kim. (2003). Protein grafting of an HIV-1 inhibiting epitope. *Proc. Natl. Acad. Sci.*, 100, 9756-9761. PMCID: PMC187838.
 - b. <u>S.K. Sia</u>, P.A. Carr, A.G. Cochran, V.N. Malashkevich, P.S. Kim. (2002). Mechanism of short, constrained alpha-helical peptides that inhibit HIV-1 entry. *Proc. Natl. Acad. Sci.*, 99, 14664-14669. (rated by Faculty of 1000 as "must-read" article). PMCID: PMC137476

Complete List of Published Work in MyBibliography:

http://www.ncbi.nlm.nih.gov/sites/myncbi/1V_xghsXBgH5X/bibliography/48097030/public/?sort=date&direction=ascending